All News | RheumNow

All News

key solution goal plan problem solve

Diagnostic tools in autoinflammatory syndromes

Save

d Olga Petryna, MD

Nov 10, 2020

With broader awareness about the disease state, early diagnosis and treatment in autoinflammatory syndromes, and its life threatening complication Macrophage Activation Syndrome, remains a huge unmet need.

Read Article

heart.jpg (keep)

FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat

Save

d Meral K. El Ramahi, MD, FACP, FACR

Nov 10, 2020

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc

Read Article

covid19.logo_.jpg

Answering questions on how COVID-19 affects rheumatic patients

Save

d Jeffrey Sparks

Nov 10, 2020

As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.

Read Article

physical therapy

Systemic Sclerosis and Physical Therapy

Save

d Sheila Reyes, MD

Nov 09, 2020

Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure.

Read Article

Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h

Links:

#ACR20 Healthcare Social Media Analytics

Steven Echard, CAE StevenEchard ( View Tweet)

Nov 10, 2020

Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj

Links:

DEFINE_ME

The Lancet TheLancet ( View Tweet)

Nov 10, 2020

Congrats to Dr @DrDavidKarp on your installation as president of @ACRheum and thanks Dr Ellen Gravallese outgoing president on your outstanding leadership in this year! #ACR20 https://t.co/q0r5URWrEr

Angus Worthing MD AngusWorthing ( View Tweet)

Nov 10, 2020

There are a number of important mimics of IgG4-RD that should be considered 🔵ANCA-associated vasculitis 🔵Multicentric Castleman’s disease 🔵Rosai-Dorfman disease 🔵Inflammatory myofibroblastic tumour 🔵Cutaneous plasmacytosis 🔵Erdheim-Chester disease 🔵Malignancy #ACR20

Chris Wincup chriswincup ( View Tweet)

Nov 10, 2020

Check out our article titled Undifferentiated Autoinflammatory Syndrome Called VEXAS by @RheumNow. We recap Saturday's session on autoinflammatory syndromes featuring Dr. Dan Kastner. #ACR20 https://t.co/afNK3UuZef https://t.co/qGvC2ylmjL

Links:

https://bit.ly/3kdpG9v

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020

Want the highlights of #ACR20 Day 4? Check out our podcast through the link below or through Apple and Android podcasts. Just look up "Rheum Now". https://t.co/EHcrkIxAez https://t.co/K2pzQPcgdB

Links:

https://bit.ly/3eERGBC

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020

The folly of dietary restriction in contemporary gout? by @RichardPAConway Dr. Conway discusses the abstracts presented at #ACR20 https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS

Links:

https://bit.ly/3keE0OW

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020

Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey ) COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20 https://t.co/T2iUwE7XUo https://t.co/AyQ6X2fOJA

Links:

https://bit.ly/32qLXdK

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020

Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc

Links:

https://bit.ly/2Id7jnQ

Dr. John Cush RheumNow ( View Tweet)

Nov 10, 2020

TAK & GCA differ in vessel involvement when it comes to the 👁👁 > TAK- large vessel lesions > GCA- small vessel vasculitis @RheumNow #ACR20 https://t.co/sa4VEvCKOt

sheila RHEUMarampa ( View Tweet)

Nov 09, 2020

I would usually be on a Transatlantic flight at this point post-ACR. Going #virtual is great as I never left. What did you miss most about a face to face conference? @RheumNow #ACR20

Dr. Antoni Chan synovialjoints ( View Tweet)

Nov 09, 2020

Dr. Cush and Dr. Kavanaugh recaps the #ACR20 meeting during #RheumatologyRoundUp highlighting important studies that were presented during the mtg and how they might impact practices. Log into https://t.co/3hCmtuN7kj to view this and all our videos/news stories. @RheumNow https://t.co/HgiA1QrdIX

Links:

Home | RheumNow

k dao KDAO2011 ( View Tweet)

Nov 09, 2020

IgG4-RD tx: GCs are mainstay tx starting at 30-40mg/d tapered gradually but 30% of pts will have recurrences Potential therapeutic targets to ⬇GC toxicity ✏B cell/plasmablasts (promising) ✏T cells (anecdotal) @RheumNow #ACR20 https://t.co/X2NI3vFUgl

sheila RHEUMarampa ( View Tweet)

Nov 09, 2020

”Somatic mutation (in UBA1) may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Kastner. Have you seen VEXAS in your clinic? #ACR20

Dr. Rachel Tate uptoTate ( View Tweet)

Nov 09, 2020

Reflecting on my first @ACRheum Congress- it wasn’t how I expected my first ACR to be. But #ACR20 was brilliant given the circumstances! Easily one of the best virtual events I’ve attended- smooth platform, huge variety of sessions and efficient on-demand service. @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020

Spot diagnosis @RheumNow @CRASCRRheum #ACR20 hint this woman has 2 rheumatic diseases https://t.co/kEu9COJY3B

Janet Pope Janetbirdope ( View Tweet)

Nov 09, 2020

×